Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose: Phase II multicenter study investigated the efficacy and toxicity of the novel halogenated derivative of sulfaquixonaline Chloroquinoxaline Sulfonamide (CQS) in metastatic colorectal cancer. Experimental design: Eligible patients with metastatic or recurrent colorectal cancer received CQS at a dose schedule of 2000 mg/m2 over an hour weekly for 4 weeks every 42 days. Treatment was continued until unexpected toxicity or disease progression. Results: A total of seventeen patients were enrolled on this study. 94% of all patients enrolled had prior treatment. Sixteen patients were evaluable for response with fifteen patients showing evidence of disease progression and one patient with prolonged stable disease. One patient had non-evaluable disease. Following this interim analysis, the drug was considered ineffective and the study was terminated early. The most frequent adverse event was anemia. No patients discontinued the treatment because of toxicity. Conclusion: CQS, when given at a dose of 2000 mg/m2 weekly for 4 weeks every 42 days to patients with metastatic colorectal cancer, does not result in significant tumor regression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55(1):10–0, 2005

    Article  PubMed  Google Scholar 

  2. Pazdur R., Coia LR, Wagman LD, Ayoub JP: Colorectal and Anal Cancers. In: Cancer Management: A Mulitidisciplinary Approach. Third Edition. Ed. By Pazdur R, Coia L, Hoskins WJ,Wagman LD. PRRR, Huntington NY, 1999

    Google Scholar 

  3. Tong WP, Hartshorn J, Mathews LA: Chloroquinoxaline sulfonamide, investigational drug brochure. National Cancer Institute, Division of Cancer treatment, 1987

  4. Branda RF, McCormack JJ, Perlmutter CA: Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol. 37(23):4557–564, 1988

    Article  CAS  PubMed  Google Scholar 

  5. Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM: Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIa/β poision. Cancer Res 60: 5937–940, 2000

    CAS  PubMed  Google Scholar 

  6. Hickey R, Schiffer J, Wei Y, Malkas L: DNA synthesis is differentially affectd by the drugs mebarone and chloroquinoxaline. Proc Am Assoc Cancer Res 34:352, 1993

    Google Scholar 

  7. Branda RF, Moore AL, McCormack JJ: Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol 38: 3521–526, 1989

    Article  CAS  PubMed  Google Scholar 

  8. Rigas JR, Tong WP, Kris MG, Orazem JP, Young CW, Warrell RP Jr: Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide. Cancer Res 52(23):6619–623, 1992

    CAS  PubMed  Google Scholar 

  9. Conley BA, O’Hara S, Wu S, Melink TJ, Parnes H, Pardoe E, Egorin MJ, Van Echo DA: Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 37(1–2):139–49, 1995

    Article  CAS  PubMed  Google Scholar 

  10. Rigas JR, Francis PA, Miller VA, Tong WP, Roistacher N, Kris MG, Orazem JP, Young CW, Warrell RP Jr: Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol 35(6):483–88, 1995

    Article  CAS  PubMed  Google Scholar 

  11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92(3):205–16, 2000

    Article  CAS  PubMed  Google Scholar 

  12. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III Trial. JCO 2059–069, 2003

  13. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–37, 2004

    Article  CAS  PubMed  Google Scholar 

  14. Kim R, Ohi Y, Inoue H, Toge T: Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res. 19(6B):5393–398, 1999

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, The Ohio State University-James Cancer Hospital, Columbus, OH

    Tanios S. Bekaii-Saab, Amir Mortazavi & Eric H. Kraut

  2. Department of Pharmacology, The Ohio State University, Columbus

    Tanios S. Bekaii-Saab

  3. Central Baptist Hospital, Lexington, KY

    Lee G. Hicks

  4. Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI

    Mark Zalupski

  5. Division of Hematology and Oncology, Cleveland Clinic, Cleveland, OH

    Robert J. Pelley

  6. Colleges of Pharmacy and Medicine and Public Health, The Ohio State University, Columbus, OH

    Kenneth K. Chan

Authors
  1. Tanios S. Bekaii-Saab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Mortazavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lee G. Hicks
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Zalupski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert J. Pelley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth K. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eric H. Kraut
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bekaii-Saab, T.S., Mortazavi, A., Hicks, L.G. et al. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Invest New Drugs 24, 343–346 (2006). https://doi.org/10.1007/s10637-005-4827-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-005-4827-3

Keywords

Search

Navigation